Riluzole (100 mg)

DRUG3 trials

Sponsors

Genuv Inc., PhenoNet, Inc., AB Science

Conditions

Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis (ALS)

Phase 1

Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)

TerminatedNCT04326283

Genuv Inc.Amyotrophic Lateral Sclerosis

Start: 2020-04-02End: 2023-04-28Updated: 2023-05-09

Phase 2

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

RecruitingNCT07142291

PhenoNet, Inc.Amyotrophic Lateral Sclerosis (ALS)

Start: 2025-11-25End: 2027-06-01Target: 105Updated: 2026-07-23

Phase 3

Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients

Not yet recruitingNCT07174492

AB ScienceAmyotrophic Lateral Sclerosis (ALS)

Start: 2026-01-01End: 2029-12-31Target: 412Updated: 2025-10-03